Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Large Increase in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 2,490,000 shares, an increase of 8.3% from the September 15th total of 2,300,000 shares. Currently, 2.9% of the shares of the stock are short sold. Based on an average daily volume of 423,800 shares, the days-to-cover ratio is currently 5.9 days.

Compass Therapeutics Trading Down 3.8 %

Shares of NASDAQ:CMPX traded down $0.07 on Thursday, hitting $1.91. The company had a trading volume of 2,218,530 shares, compared to its average volume of 432,007. The company has a market cap of $262.11 million, a PE ratio of -5.29 and a beta of 0.90. The business has a 50 day moving average of $1.57 and a 200 day moving average of $1.40. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The firm had revenue of $0.85 million during the quarter. As a group, equities analysts predict that Compass Therapeutics will post -0.42 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on CMPX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, August 12th. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Monday, September 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a research report on Wednesday, August 7th.

Institutional Trading of Compass Therapeutics

A number of hedge funds have recently bought and sold shares of CMPX. Cubist Systematic Strategies LLC acquired a new position in Compass Therapeutics in the 2nd quarter valued at $41,000. Panagora Asset Management Inc. purchased a new stake in shares of Compass Therapeutics in the second quarter valued at $68,000. SG Americas Securities LLC increased its stake in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after purchasing an additional 5,515 shares during the last quarter. Bleakley Financial Group LLC purchased a new position in Compass Therapeutics during the first quarter worth about $80,000. Finally, Ground Swell Capital LLC purchased a new position in Compass Therapeutics during the second quarter worth about $124,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.